Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy.

@article{Besson2001ChangesIA,
  title={Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy.},
  author={Caroline Besson and Aicha Goubar and Jean Gabarre and Willy Rozenbaum and Gilles Pialoux and F P Ch{\^a}telet and Christine Katlama and F. Charlotte and Bertrand F Dupont and Nicole Brousse and Michel R Huerre and Jacqueline Mikol and Philippe Camparo and Karima Mokhtari and Micheline Tulliez and Dominique Salmon-C{\'e}ron and François Boué and Dominique Costagliola and Martine Rapha{\"e}l},
  journal={Blood},
  year={2001},
  volume={98 8},
  pages={
          2339-44
        }
}
HIV infection is associated with a high incidence of AIDS-related lymphomas (ARLs). Since the use of highly active antiretroviral therapy (HAART), the incidence of AIDS-defining illnesses has decreased, leading to a significant improvement in survival of HIV-infected patients. The consequences of HAART use on ARL are under debate. This study compared the incidence and the characteristics of ARL before and after the use of HAART in a large population of HIV-infected patients in the French… 

Figures and Tables from this paper

Acquired immunodeficiency syndrome-related lymphoma in the era of highly active antiretroviral therapy.
TLDR
The effects that HAART has had on acquired immunodeficiency syndrome (AIDS)-related non-Hodgkin's lymphoma (NHL) are addressed and metaanalysis of numerous cohort studies confirmed that the incidence of AIDS-related NHL has decreased.
AIDS-Related Non-Hodgkin's Lymphoma in the Era of Highly Active Antiretroviral Therapy
TLDR
High-dose chemotherapy (HDCT) and autologous stem cell rescue (ASCT) can be effective for a subset of patients with relapsed ARL and HIV sero-status alone should not preclude consideration of ASCT in the setting of ARL relapse.
Non-AIDS-defining malignancies among HIV-infected patients in the highly active antiretroviral therapy era
  • R. Bedimo
  • Medicine, Biology
    Current HIV/AIDS reports
  • 2008
TLDR
A high index of suspicion for malignancies among HIV care providers and a renewed focus on understanding the mechanisms underlying the increased rates of non-ADM rates are recommended.
HIV-related lymphoma
TLDR
The biology and changes in epidemiology of HIV-related lymphoma are discussed, and other key developments in the management of this disease are reviewed.
Cumulative HIV viremia during highly active antiretroviral therapy is a strong predictor of AIDS-related lymphoma.
TLDR
Cumulative HIV viremia is an independent and strong predictor of AIDS-related lymphoma among patients receiving HAART and the influence of cumulative HIV viresmia may differ between lymphoma subtypes.
Management of AIDS-related lymphoma
  • A. Levine
  • Medicine, Biology
    Current opinion in oncology
  • 2008
TLDR
High-dose chemotherapy with autologous stem cell transplant is associated with long-term, disease-free survival in approximately 50–80% of patients with relapsed/refractory AIDS-lymphoma, and addition of rituximab isassociated with improved response rates, without an increase in infections.
Beneficial effect of highly active antiretroviral therapy on the prognosis of AIDS-related systemic non-Hodgkin lymphomas.
TLDR
HAART has significantly improved the survival and EFS in patients with ARL, independently of chemotherapy regimen, and no influence on outcome was found for other variables except for prior AIDS and bone marrow involvement.
Evolving epidemiology of malignancies in HIV
TLDR
Prevention and screening management procedures need to be assessed on the basis of specific evidence-based studies in the HIV-infected population and the respective role of HIV itself, immunosuppression, and antiretrovirals as pro-oncogenic factors needs to be further examined.
Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma
TLDR
Efficacy of HAART was independently associated with prolonged survival in this large cohort of patients with ARL and information on patient's response to HAART is crucial for the evaluation of future treatment strategies.
...
...

References

SHOWING 1-10 OF 41 REFERENCES
Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy.
TLDR
The incidence of ARL has not changed over time, but contributes to a greater percentage of first AIDS-defining illnesses (ADI) in the HAART era, and older age, nadir CD4 count, and no prior HAART use, predict the development of ARl.
Combination antiretroviral therapy and incidence of AIDS-related malignancies.
TLDR
The decline in Kaposi's sarcoma cannot be explained by earlier declines in HIV incidence, and concurrent increases in antiretroviral therapy suggests that control of viral replication may lead to a direct or indirect effect on KS pathogenesis.
Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: prospective cohort study
The rate of progression to new AIDS defining events has been reduced considerably since the introduction of potent antiretroviral combination therapy.1 2 It is unclear, however, whether the reduction
Impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphomas among HIV-1-infected individuals. Multicenter AIDS Cohort Study.
TLDR
Using data from the Multicenter AIDS Cohort Study, a longitudinal cohort study of the natural history of HIV-1 infection among homosexual men, the incidence rates of Kaposi's sarcoma and non-Hodgkin's lymphoma over calendar time were determined and an impact on NHL was not observed.
Evolving characteristics of AIDS-related lymphoma.
TLDR
Significant changes in the demographic profile of patients with newly diagnosed ARL have occurred, with the later time intervals associated with a higher prevalence in women and Latinos, and the pathologic spectrum of disease has changed, with a decrease in the prevalence of small noncleaved lymphoma and an increase in diffuse large cell lymphoma.
Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults.
  • Johnson
  • Medicine
    Journal of the National Cancer Institute
  • 2000
TLDR
Since the widespread use of HAART, there have been substantial reductions in the incidence Kaposi's sarcoma and non-Hodgkin's lymphoma in HIV-infected people but, so far, no substantial change in the occurrence of other cancers.
Acquired immunodeficiency syndrome-related lymphoma: clinical aspects.
TLDR
Low-dose combination chemotherapy has been associated with complete remission (CR) rates of 41% to 46%, with an overall median survival time of 8.7 months, similar to results achieved with standard-dose therapy, which is associated with greater toxicity.
Effect of antiretroviral therapy on recent trends in selected cancers among HIV-infected persons. Adult/Adolescent Spectrum of HIV Disease Project Group.
TLDR
Although for KS the decline occurred in both treated and untreated groups (difference in rate of decline not significant, p = .08), it was sharper in the treated group; additionally, KS declined faster in the era after highly active antiretroviral agents were introduced, thus, these decreases may be due in part to the effect of antireTroviral therapy slowing the progression of HIV disease.
Altered natural history of AIDS-related opportunistic infections in the era of potent combination antiretroviral therapy.
TLDR
The available data regarding recent trends in AIDS-related opportunistic infections incidence and manifestations, and clinical and immunologic evidence that potent combination antiretroviral therapy can alter the natural history of these opportunism infections are reviewed, are reviewed.
...
...